| Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth G Germano, S Lamba, G Rospo, L Barault, A Magrì, F Maione, M Russo, ... Nature 552 (7683), 116-120, 2017 | 630 | 2017 |
| Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... Cancer discovery 6 (2), 147-153, 2016 | 427 | 2016 |
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus F Di Nicolantonio, S Arena, J Tabernero, S Grosso, F Molinari, ... The Journal of clinical investigation 120 (8), 2858-2866, 2010 | 408 | 2010 |
| Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019 | 387 | 2019 |
| The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets E Medico, M Russo, G Picco, C Cancelliere, E Valtorta, G Corti, ... Nature communications 6 (1), 7002, 2015 | 324 | 2015 |
| Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ... Cancer discovery 6 (1), 36-44, 2016 | 314 | 2016 |
| Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 304 | 2014 |
| Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ... Clinical cancer research 21 (9), 2157-2166, 2015 | 297 | 2015 |
| Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ... Cancer Cell 34 (1), 148-162. e7, 2018 | 150 | 2018 |
| RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells S Lamba, M Russo, C Sun, L Lazzari, C Cancelliere, W Grernrum, ... Cell reports 8 (5), 1475-1483, 2014 | 132 | 2014 |
| Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses F Di Nicolantonio, S Arena, M Gallicchio, D Zecchin, M Martini, SE Flonta, ... Proceedings of the National Academy of Sciences 105 (52), 20864-20869, 2008 | 116 | 2008 |
| A vulnerability of a subset of colon cancers with potential clinical utility L Vecchione, V Gambino, J Raaijmakers, A Schlicker, A Fumagalli, ... Cell 165 (2), 317-330, 2016 | 110 | 2016 |
| A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin S Arena, G Corti, E Durinikova, M Montone, NM Reilly, M Russo, ... Clinical Cancer Research 26 (6), 1372-1384, 2020 | 86 | 2020 |
| Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016; 6: 36–44. doi: 10.1158/2159-8290 M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ... CD-15-0940.[Abstract][CrossRef][Academic Search], 0 | 45 | |
| Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016; 6: 147–153. doi: 10.1158/2159-8290 M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... CD-15-1283.[Europe PMC free article][Abstract][CrossRef][Academic Search], 0 | 39 | |
| A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells M Russo, S Pompei, A Sogari, M Corigliano, G Crisafulli, A Puliafito, ... Nature Genetics 54 (7), 976-984, 2022 | 35 | 2022 |
| Climbing RAS, the everest of oncogenes M Russo, F Di Nicolantonio, A Bardelli Cancer discovery 4 (1), 19-21, 2014 | 31 | 2014 |
| Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis M Martini, M Russo, S Lamba, E Vitiello, EH Crowley, F Sassi, ... Cancer research 73 (6), 1912-1921, 2013 | 22 | 2013 |
| Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies M Russo, S Lamba, A Lorenzato, A Sogari, G Corti, G Rospo, B Mussolin, ... Nature Communications 9 (1), 2287, 2018 | 20 | 2018 |
| Adaptive evolution: how bacteria and cancer cells survive stressful conditions and drug treatment M Russo, A Sogari, A Bardelli Cancer Discovery 11 (8), 1886-1895, 2021 | 19 | 2021 |
